Bimekizumab in Hidradenitis Supprativa (HS) - results of 2 phase III BE HEARD I & II trials show Week 16 50% HS Responses to be 48% and 52% (vs PBO 29% and 32%). >75% maintained response out to wk 48; at wk 48, a 75% HS response seen in 55%. https://t.co/vAMPWV1gKi
Links:
AAD: Awaiting FDA decision in psoriasis, UCB touts 48-week data for bimekizumab…
https://bit.ly/41EOvCz
Dec-22-2023
